BRPI0520677A2 - identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina - Google Patents

identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina

Info

Publication number
BRPI0520677A2
BRPI0520677A2 BRPI0520677-4A BRPI0520677A BRPI0520677A2 BR PI0520677 A2 BRPI0520677 A2 BR PI0520677A2 BR PI0520677 A BRPI0520677 A BR PI0520677A BR PI0520677 A2 BRPI0520677 A2 BR PI0520677A2
Authority
BR
Brazil
Prior art keywords
fibronectin
characterization
identification
blocking function
function antibodies
Prior art date
Application number
BRPI0520677-4A
Other languages
English (en)
Inventor
Andreas Menrad
Josef Prassler
Armin Weidmann
Original Assignee
Bayer Schering Pharma Ag
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Morphosys Ag filed Critical Bayer Schering Pharma Ag
Publication of BRPI0520677A2 publication Critical patent/BRPI0520677A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

IDENTIFICAçãO E CARACTERIZAçãO DE ANTI-CORPOS DE FUNçãO DE BLOQUEIO ANTI-ED-B-FIBRONECTINA. A presente invenção refere-se aos polipeptídeos recombinantes, especialmente aos anticorpos ou fragmentos de anticorpos, que ligam a isoforma ED-B da fibronectina e podem bloquear sua função. Além disso, é publicada a aplicação diagnóstica e farmacêutica dos polipeptídeos de acordo com a invenção.
BRPI0520677-4A 2005-11-09 2005-11-09 identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina BRPI0520677A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/012185 WO2007054120A1 (de) 2005-11-09 2005-11-09 Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern

Publications (1)

Publication Number Publication Date
BRPI0520677A2 true BRPI0520677A2 (pt) 2009-05-19

Family

ID=36170357

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520677-4A BRPI0520677A2 (pt) 2005-11-09 2005-11-09 identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina

Country Status (8)

Country Link
EP (1) EP1945767B1 (pt)
JP (1) JP2009514540A (pt)
CN (1) CN101356271A (pt)
AT (1) ATE463512T1 (pt)
BR (1) BRPI0520677A2 (pt)
CA (1) CA2628552A1 (pt)
DE (1) DE502005009389D1 (pt)
WO (1) WO2007054120A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
KR20100128291A (ko) 2008-02-14 2010-12-07 브리스톨-마이어스 스큅 컴퍼니 Ｅｇｆｒ에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
CN102753569A (zh) 2009-12-14 2012-10-24 塞尔蛋白质股份有限公司 对纤维连接蛋白额外结构域b具有特异结合活性的修饰的泛素蛋白
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
US9492572B2 (en) 2011-06-15 2016-11-15 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
WO2013186329A1 (en) 2012-06-13 2013-12-19 Scil Proteins Gmbh Human fusion proteins comprising single chain tnfalpha and targeting domains
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
ES2916101T3 (es) 2015-07-16 2022-06-28 Navigo Proteins Gmbh Nuevas proteínas de unión a inmunoglobulina y su uso en la purificación por afinidad
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
US20180340936A1 (en) * 2015-11-16 2018-11-29 Hefei Lifeon Pharmaceutical Co. Ltd. Use of ed-b protein in diagnosis of tissue hyperplasia
CN109310780A (zh) 2016-05-04 2019-02-05 纳维格蛋白质有限公司 包含肽接头的用于化学部分位点-特异性偶联的靶向化合物
EP3497117B1 (en) 2016-08-11 2024-01-24 Navigo Proteins GmbH Novel alkaline stable immunoglobulin-binding proteins
WO2018217351A1 (en) 2017-05-24 2018-11-29 Tets Viktor Veniaminovich Methods for treating and preventing diseases
WO2019062877A1 (zh) 2017-09-30 2019-04-04 合肥立方制药股份有限公司 结合至纤维连接蛋白b结构域的蛋白
EP3787638A4 (en) * 2018-04-30 2023-10-18 Tets, Viktor, Veniaminovich TETZ PROTEINS AND PRION-LIKE PROTEINS AND RELATED METHODS
US11918610B2 (en) 2018-06-29 2024-03-05 Viktor Veniaminovich Tets Methods for diagnosis and treatment of type 1 diabetes
US12545965B2 (en) 2018-07-03 2026-02-10 Viktor Veniaminovich Tets Method for assessing and inhibiting aging and means of determining biological age
SG11202105029WA (en) 2018-12-18 2021-06-29 Navigo Proteins Gmbh Novel folr1 specific binding proteins for cancer diagnosis and treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
IL142025A0 (en) 1999-07-20 2002-03-10 Morphosys Ag Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds
AU2001227837A1 (en) * 2000-01-12 2001-07-24 Light Sciences Corporation Novel treatment for eye disease
AU4243201A (en) 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
DE50114321D1 (de) 2000-09-07 2008-10-23 Bayer Schering Pharma Ag REZEPTOR DER EDb-FIBRONEKTIN-DOMÄNE (II)

Also Published As

Publication number Publication date
EP1945767A1 (de) 2008-07-23
CN101356271A (zh) 2009-01-28
EP1945767B1 (de) 2010-04-07
DE502005009389D1 (de) 2010-05-20
ATE463512T1 (de) 2010-04-15
JP2009514540A (ja) 2009-04-09
CA2628552A1 (en) 2007-05-18
WO2007054120A1 (de) 2007-05-18

Similar Documents

Publication Publication Date Title
BRPI0520677A2 (pt) identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
NO20074563L (no) Novel anti-plgf antibody
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
NO20085362L (no) Hoyaffinitets humane og humaniserte anti-alfa5 beta1-integrin funksjonsblokkerende antistoffer med redusert immunogenisitet
EA200700847A1 (ru) Материалы, связывающие прионные белки, и способы их применения
DK1951759T3 (da) Anti-EGFR-antistoffer
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
BR112012007523A2 (pt) moléculas de anticorpo anti-gcc e composições e métodos relacionados
EA201100694A1 (ru) Антитело к cd38 человека и его применение
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
GEP20115226B (en) P-cadherin antibodies
ATE484749T1 (de) Von anti-trichinella-antikörpern erkannte polypeptide und ihre verwendung
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
WO2006086799A3 (en) Prion-specific peptide reagents
WO2010009856A3 (en) Goodpasture antigen binding protein and its detection
WO2007039256A3 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
DE602006018424D1 (de) Peptide zum nachweis von ehrlichia ewingii antikörper
WO2006094828A3 (en) Monoclonal antibodies and immunodetection assay specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor
MXPA06001287A (es) Identificacion y caracterizacion de anticuerpos anti-ed-b-fibronectina bloqueantes de la funcion.
TR200600421A2 (tr) Fonksiyon bloke eden anti-ED-B-fibronektin antikorların teşhisi ve karakterizasyonu

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MORPHOSYS AG (DE)

Free format text: TRANSFERIDO DE: BAYER SCHERING PHARMA AG

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 6A ANUIDADE.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/18 (2006.01), A61K 39/00 (2006.01), A61P 3